Olumiant Olumiant [Member] Olumiant [Member] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Damages awarded, value Loss Contingency, Damages Awarded, Value Line of credit facility, maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Other changes in operating assets and liabilities, net of acquisitions and divestitures: Increase (Decrease) in Operating Capital [Abstract] Lebrikizumab Lebrikizumab [Member] Lebrikizumab [Member] Neuroscience Neuroscience [Member] Revenue to unaffiliated customers, Neuroscience Proceeds from sale of product rights Proceeds from Sale of Intangible Assets Award Type [Domain] Award Type [Domain] Fair Value as of Grant Date Award Grant Date Fair Value 7.125% notes due 2025 7.125% Notes Due 2025 [Member] 7.125% Notes Due 2025 Acquired in-process research and development (Note 3) Research and Development Asset Acquired Other than Through Business Combination, Writeoff Schedule of Recognized Identified Assets Acquired and Liabilities Assumed Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Equity method investments Other Long-Term Investments Accounts receivable derecognized Transfer of Financial Assets Accounted for as Sales, Amount Derecognized Inventories Deferred Tax Liabilities, Inventory Revenue, information used to determine revenue recognized, change in accounting estimate, percent (or less) Revenue, Information Used To Determine Revenue Recognized, Change In Accounting Estimate, Percent Revenue, Information Used To Determine Revenue Recognized, Change In Accounting Estimate, Percent 1.375% Notes due 2061 1.375% euro denominated notes due 2061 1.375% Euro Denominated Notes Due 2061 [Member] 1.375% Euro Denominated Notes Due 2061 Insider Trading Policies and Procedures [Line Items] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Other receivables Derivative Asset, Current Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] 2028 Lessee, Operating Lease, Liability, to be Paid, Year Five Schedule of Research and Development Assets Acquired Other than Through Business Combination Schedule of Research and Development Assets Acquired Other than Through Business Combination [Table Text Block] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Shareholders' Equity Equity [Text Block] Rigel Pharmaceuticals, Inc. Rigel Pharmaceuticals, Inc. [Member] Rigel Pharmaceuticals, Inc. Schedule of Equity [Line Items] Subsidiary or Equity Method Investee [Line Items] Marketable equity securities Marketable Securities [Member] Marketable Securities [Member] Defined Benefit Plan, Pension Plan with Project Benefit Obligation in Excess of Plan Assets [Abstract] Defined Benefit Plan, Pension Plan with Project Benefit Obligation in Excess of Plan Assets [Abstract] Inventory write-down Inventory Write-down Expected dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Impairment, Intangible Asset, Indefinite-Lived (Excluding Goodwill), Statement of Income or Comprehensive Income [Extensible Enumeration] Impairment, Intangible Asset, Indefinite-Lived (Excluding Goodwill), Statement of Income or Comprehensive Income [Extensible Enumeration] Customer [Axis] Customer [Axis] Schedule of Assumptions Used Defined Benefit Plan, Assumptions [Table Text Block] Current Liabilities Liabilities, Current [Abstract] Federal Deferred Federal Income Tax Expense (Benefit) Purchases of in-process research and development Payments to Acquire in Process Research and Development Subsequent Event Type [Domain] Subsequent Event Type [Domain] Diluted (in dollars per share) Earnings Per Share, Diluted AOCI Attributable to Parent [Abstract] AOCI Attributable to Parent [Abstract] Accounts receivable, net of allowances of $14.8 (2023) and $16.0 (2022) Accounts Receivable, after Allowance for Credit Loss, Current Rate of compensation increase Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase Extinguishment of debt, amount Extinguishment of Debt, Amount Schedule of Net Periodic (Benefit) Costs Schedule of Net Benefit Costs [Table Text Block] Litigation Case [Axis] Litigation Case [Axis] Trading Symbol Trading Symbol U.S. government and agency securities US Government Agencies Debt Securities [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Cash acquired Cash Acquired from Acquisition Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Designated Unusable Designated Unusable [Member] Those operating loss/tax credit carryforwards/carrybacks included that have been designated to be unusable and therefore, is fully reserved. Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Benefits paid Defined Benefit Plan, Plan Assets, Benefits Paid Carrying Amount, Gross Intangible Assets, Gross (Excluding Goodwill) Fair value adjustment on hedged long-term notes Long-term Debt, Fair Value Adjustment Fair value adjustment to carrying value of long term debt to arrive at total fair value. Prepaid taxes Prepaid Taxes Proceeds from sales of and distributions from noncurrent investments Proceeds from Sale and Maturity of Other Investments Contract liabilities Contract with Customer, Liability Unfunded commitments to invest in venture capital funds Fair Value, Investments, Entities that Calculate Net Asset Value Per Share, Unfunded Commitments Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Service cost Service cost Defined Benefit Plan, Service Cost Unfunded commitments to invest in venture capital funds, anticipated payment period Fair Value, Investments, Entities That Calculate Net Asset Value Per Share, Unfunded Commitments, Payment Period Fair Value, Investments, Entities That Calculate Net Asset Value Per Share, Unfunded Commitments, Payment Period Executive Category: Executive Category [Axis] Unrecognized prior service (benefit) cost Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, Prior Service Cost (Credit), before Tax Quoted Prices in Active Markets for Identical Assets (Level 1) Fair Value, Inputs, Level 1 [Member] Total deferred tax assets Deferred Tax Assets, Net of Valuation Allowance Carrying Amount Reported Value Measurement [Member] Property, Plant and Equipment Property, Plant and Equipment [Table Text Block] Equity Components [Axis] Equity Components [Axis] Financial Instruments [Domain] Financial Instruments [Domain] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Revenue, performance obligation, sales returns, percentage of net revenue (less than) Revenue, Performance Obligation, Sales Returns, Percentage Of Net Revenue Revenue, Performance Obligation, Sales Returns, Percentage Of Net Revenue Hedging Relationship [Domain] Hedging Relationship [Domain] No Expiration No Expiration [Member] Those operating loss/tax credit carryforwards/carrybacks included that have no expiration. Number of shares available for grant (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant 2025 Long-Term Debt, Maturity, Year Two Entity Small Business Entity Small Business 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Four Local Phone Number Local Phone Number Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Derivative, notional amount Derivative, Notional Amount Accounts Receivable Accounts Receivable [Member] Other foreign countries Other foreign countries Other Foreign Countries [Member] Other Foreign Countries [Member] Potential achievements Collaborative Arrangement, Rights and Obligations, Rights (Obligations) Collaborative Arrangement, Rights And Obligations, Rights (Obligations) Ebglyss Ebglyss [Member] Ebglyss Retirement Plan Type [Domain] Retirement Plan Type [Domain] Restricted Stock Units (RSUs) Restricted Stock Units (RSUs) [Member] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Basaglar Basaglar [Member] Basaglar [Member] Depreciation expense Depreciation Stock-based compensation Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount Retirement Benefits [Abstract] Retirement Benefits [Abstract] Asset impairment, restructuring, and other special charges (Note 5) Total asset impairment, restructuring, and other special charges Restructuring, Settlement and Impairment Provisions Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] Chugai Chugai [Member] Chugai Summary of Long-term Notes Schedule of Long-Term Debt Instruments [Table Text Block] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Research and development Research and Development Expense (Excluding Acquired in Process Cost) Contingent value right, monthly reduction Business Acquisition, Contingent Value Right, Regulatory Approval Delay, Monthly Reduction Business Acquisition, Contingent Value Right, Covenant, Regulatory Approval Occurs Revenue (Note 2) Revenue Revenues Prepaid employee benefits Deferred Tax Liabilities, Prepaid Expenses Unfavorable Regulatory Action Unfavorable Regulatory Action [Member] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Precision Biosciences, Inc. Precision Biosciences, Inc. [Member] Precision Biosciences, Inc. Award Type [Axis] Award Type [Axis] Grants in period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag Hedging Designation [Axis] Hedging Designation [Axis] Property and equipment, gross Property, Plant and Equipment, Gross Revenue, performance obligation, payment terms, financing component, period between transfer of control and payment receipt (or less) Revenue, Performance Obligation, Payment Terms, Financing Component, Period Between Transfer Of Control And Payment Receipt Revenue, Performance Obligation, Payment Terms, Financing Component, Period Between Transfer Of Control And Payment Receipt Right-of-use assets obtained in exchange for new operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Effective portion of risk-management instruments that was recognized in other comprehensive income (loss) Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax Less imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Reclassification [Line Items] Reclassification [Line Items] Employer contribution Defined Benefit Plan, Plan Assets, Contributions by Employer PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount 4.5% Notes Due 2027 4.5% Notes Due 2027 [Member] 4.5% Notes Due 2027 Leases Lessee, Finance Leases [Text Block] Expected return on plan assets Defined Benefit Plan, Expected Return (Loss) on Plan Assets Schedule of Components of Income Tax Expense Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Taltz® Taltz [Member] Taltz [Member] Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards [Line Items] LIFO inventory amount LIFO Inventory Amount Prepaid expenses Prepaid Expense, Current Issuance of stock under employee stock plans, net (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans 3.95% notes due 2049 3.95% Notes Due 2049 [Member] 3.95% Notes Due 2049 [Member] 2026 Lessee, Operating Lease, Liability, to be Paid, Year Three Changes related to the impact of foreign currency translation Unrecognized Tax Benefits, Decrease Resulting from Foreign Currency Translation Verzenio® Verzenio [Member] Verzenio [Member] Other comprehensive income (loss) before reclassifications OCI, before Reclassifications, Net of Tax, Attributable to Parent Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Carrying Amount, Net Finite-Lived Intangible Assets, Net Implementation of New Financial Accounting Standards New Accounting Pronouncements, Policy [Policy Text Block] Expected future employer contributions, next fiscal year Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year 4.15% notes due 2059 4.15% Notes Due 2059 [Member] 4.15% Notes Due 2059 [Member] Compensation and benefits Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits Derivative asset, notional amount Derivative Asset, Notional Amount Accumulated Amortization Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization 2025 Lessee, Operating Lease, Liability, to be Paid, Year Two Interest income Investment Income, Interest Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Weighted-average assumptions used to determine benefit obligation as of December 31: Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract] 5.95% notes due 2037 5.95% Notes Due 2037 [Member] 5.95% Notes Due 2037 Security Exchange Name Security Exchange Name Share-based Compensation, Option and Incentive Plans Share-Based Payment Arrangement [Policy Text Block] Non-deductible acquired IPR&D Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount Marketing, selling, and administrative Selling, General and Administrative Expense Accumulated other comprehensive loss (Note 17) Accumulated Other Comprehensive Income (Loss), Net of Tax Collaborations and Other Arrangements Collaborative Arrangement Disclosure [Text Block] Employee Stock Option Employee Stock Option [Member] Biopharma Global Inc Point Biopharma Global Inc [Member] Point Biopharma Global Inc Employee Litigation, July 2019 Ruling Employee Litigation, July 2019 Ruling [Member] Employee Litigation, July 2019 Ruling Maximum Maximum [Member] Schedule of Other Operating Cost and Expense, by Component Restructuring and Related Costs [Table Text Block] Total compensation cost not yet recognized Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Document Type Document Type Reclassification out of Accumulated Other Comprehensive Income [Table] Reclassification out of Accumulated Other Comprehensive Income [Table] Tabular List, Table Tabular List [Table Text Block] Other oncology Other Oncology [Member] Other Oncology [Member] Other long-term debt Other Notes Payable Employee Litigation, July 2018 Ruling Employee Litigation, July 2018 Ruling [Member] Employee Litigation, July 2018 Ruling Purchase of treasury shares Purchase for treasury Treasury Stock, Value, Acquired, Cost Method Inventories Inventory, Policy [Policy Text Block] Other current liabilities Derivative Liability, Current Hedged Fixed Rate Debt Hedged Fixed Rate Debt [Member] Hedged Fixed-Rate Debt [Member] Stock-Based Compensation Share-Based Payment Arrangement [Text Block] Federal Current Federal Tax Expense (Benefit) Carryforward Carryforward [Member] Tax Carryforward [Member] Business Acquisition [Axis] Business Acquisition [Axis] Accounts receivable, allowances Accounts Receivable, Allowance for Credit Loss, Current Derivative [Table] Derivative [Table] Customer Concentration Risk Customer Concentration Risk [Member] State Deferred State and Local Income Tax Expense (Benefit) Foghorn Therapeutics Inc. Foghorn Therapeutics Inc. [Member] Foghorn Therapeutics Inc. Accounts payable and other liabilities—increase (decrease) Increase (Decrease) in Accounts Payable and Accrued Liabilities Costs, expenses, and other: Costs and Expenses [Abstract] Title of 12(b) Security Title of 12(b) Security Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Actuarial (gain) loss Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss) Acquisitions Business Combination Disclosure [Text Block] Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] Fair value hedges: Fair Value Hedge [Abstract] Fair Value Hedge [Abstract] Change in Accounting Estimate by Type [Axis] Change in Accounting Estimate by Type [Axis] Indefinite-lived intangible assets Indefinite-Lived Intangible Assets (Excluding Goodwill) Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Alimta® Alimta [Member] Alimta [Member] Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Retiree Health Benefit Plans Postretirement Health Coverage [Member] Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Entity Tax Identification Number Entity Tax Identification Number 5.0% notes due 2026 5.0% Notes Due 2026 [Member] 5.0% Notes Due 2026 Statistical Measurement [Axis] Statistical Measurement [Axis] Entity Interactive Data Current Entity Interactive Data Current Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Swap U.S Dollars To Euro Swap U.S. Dollars To Euro [Member] Swap U.S. Dollars To Euro Net product revenue Product [Member] Goodwill and Intangible Assets Goodwill and Intangible Assets, Policy [Policy Text Block] Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer 7 1/8% Notes due 2025 7 1/8% Notes Due June 1, 2025 [Member] 7 1/8% Notes Due June 1, 2025 [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Measure: Measure [Axis] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Name Outstanding Recovery, Individual Name Other securities Other Debt Obligations [Member] Intangibles Deferred Tax Liabilities, Goodwill and Intangible Assets Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Schedule of Additional Borrowings Disclosures Schedule of Additional Borrowings Disclosures [Table Text Block] Schedule of Additional Borrowings Disclosures [Table Text Block] Advertising expense Advertising Expense Schedule of Deferred Tax Assets and Liabilities Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Buy US Dollar Sell Chinese Yuan Buy US Dollar Sell Chinese Yuan [Member] Buy US Dollar Sell Chinese Yuan Immunology Immunology [Member] Immunology [Member] Derivatives Derivatives, Policy [Policy Text Block] 2024 Finite-Lived Intangible Asset, Expected Amortization, Year One Operating cash flows from operating leases Operating Lease, Payments Zepbound® Zepbound [Member] Zepbound Sell Chinese Yuan Sell Chinese Yuan [Member] Sell Chinese Yuan Cash dividends declared Dividends Interest cost Defined Benefit Plan, Interest Cost PEO PEO [Member] Concentration Risk, Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Other Stockholders' Equity, Other Auditor Location Auditor Location Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan Disclosure [Line Items] Retirement Benefits Retirement Benefits [Text Block] Change in plan assets: Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward] Other operating activities, net Other Operating Activities, Cash Flow Statement Versanis Bio, Inc. (Versanis) Versanis Bio, Inc [Member] Versanis Bio, Inc 1.625% euro denominated notes due 2026 1.625% Euro-denominated Notes Due 2026 [Member] 1.625% Euro-denominated Notes Due 2026 Net Cash Used for Investing Activities Increase in net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Financial instruments Deferred Tax Liabilities, Derivatives Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax Expiration Between 2028 and 2042 Expiration Between 2029 and 2043 [Member] Expiration Between 2028 and 2042 [Member] Forward-starting interest rate swaps Interest Rate Swap [Member] Debt Instrument [Axis] Debt Instrument [Axis] Other noncurrent liabilities Derivative Liability, Noncurrent Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Realized gross gains on sales Available for Sale Securities and Equity Securities, FV-NI, Realized Gain Available for Sale Securities and Equity Securities, FV-NI, Realized Gain 0.15% Swiss franc denominated notes due 2024 0.15% Swiss Franc-denominated Notes Due 2024 [Member] 0.15% Swiss Franc-denominated Notes Due 2024 Projected benefit obligation Defined Benefit Plan, Pension Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation Schedule of Maturities of Long-term Debt Schedule of Maturities of Long-Term Debt [Table Text Block] Total current tax expense Current Income Tax Expense (Benefit) Volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Fair value of securities in an unrealized loss position Debt Securities, Available-for-Sale, Unrealized Loss Position Brazil BRAZIL Property and Equipment Property, Plant and Equipment Disclosure [Text Block] Gains on sale of product rights Gain (Loss) on Disposition of Intangible Assets Milestone payment received Disposal Group, Including Discontinued Operation, Milestone Payments To Be Received Disposal Group, Including Discontinued Operation, Milestone Payments To Be Received Noncurrent Liabilities Liabilities, Noncurrent [Abstract] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] 2.125% euro denominated notes due 2030 2.125% Euro-denominated Notes Due 2030 [Member] 2.125% Euro-denominated Notes Due 2030 Capitalized research and development Deferred Tax Assets, in Process Research and Development Expiration By 2027 Expiration By 2028 [Member] Expiration By 2027 [Member] Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Disposal Group, Disposed of by Sale, Not Discontinued Operations Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] Weighted-average assumptions used to determine net periodic benefit costs: Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract] 2024 Defined Benefit Plan, Expected Future Benefit Payment, Year Two Foreign currency exchange rate changes and other Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax China CHINA Benefit (expense) for income taxes related to other comprehensive income (loss) Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent Proceeds from sales Proceeds from Sale of Equity and Available for Sale Securities Proceeds from Sale of Equity and Available for Sale Securities 0.42% Japanese yen denominated notes due 2029 .42% Yen-denominated Notes Due 2029 [Member] .42% Yen-denominated Notes Due 2029 [Member] Weighted average interest rate Short-Term Debt, Weighted Average Interest Rate, at Point in Time Collaborative arrangement, rights and obligations percent (up to) Collaborative Arrangement, Rights and Obligations Percent Description of rights and obligations under the collaborative arrangements, including but not limited to - percent share in various revenues and costs, percent interest earned on related party notes. Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] State Current State and Local Tax Expense (Benefit) Total current assets Assets, Current 1-3 Years Tax Cut And Jobs Act, Toll Tax, To Be Paid, After One Through Three Years Tax Cut And Jobs Act, Toll Tax, To Be Paid, After One Through Three Years Other comprehensive income (loss): Other Comprehensive Income (Loss), before Tax [Abstract] Schedule of Equity [Table] Schedule of Subsidiary or Equity Method Investee [Table] Trulicity® Trulicity [Member] [Member] Trulicity [Member] [Member] Net periodic (benefit) cost Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Summary of Fair Value Information, Liabilities Fair Value, Liabilities Measured on Recurring Basis [Table Text Block] Other noncurrent liabilities Business Combination, Contingent Consideration, Liability 4.875% notes due 2053 4.875% Notes Due 2053 [Member] 4.875% Notes Due 2053 Marketable equity securities Defined Benefit Plan, Equity Securities [Member] Derivative Liability, Current, Statement of Financial Position [Extensible Enumeration] Derivative Liability, Current, Statement of Financial Position [Extensible Enumeration] Short-term Debt, Type [Domain] Short-Term Debt, Type [Domain] Japan JAPAN Earnings Per Share (EPS) Earnings Per Share, Policy [Policy Text Block] Goodwill and Other Intangibles Goodwill and Intangible Assets Disclosure [Text Block] Concentration risk, percentage Concentration Risk, Percentage Schedule of Accumulated Other Comprehensive Income (Loss) Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Realized gross losses on sales Available for sale Securities and Equity Securities, FV-NI, Realized Loss Available for sale Securities and Equity Securities, FV-NI, Realized Loss Weighted average grant date fair value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value 2028 Finite-Lived Intangible Asset, Expected Amortization, Year Five Ireland IRELAND Asset-backed securities Asset-Backed Securities [Member] Net Cash Provided by Operating Activities Increase in net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Schedule of Finite-Lived Intangible Assets, Future Amortization Expense Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Other current liabilities Business Combination, Contingent Consideration, Liability, Current Class of Stock [Axis] Class of Stock [Axis] Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Amortization of prior service (benefit) cost Defined Benefit Plan, Amortization of Prior Service Cost (Credit) Depreciation and amortization Depreciation, Depletion and Amortization Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Business Combination and Asset Acquisition [Abstract] Commercial Paper Commercial Paper [Member] Long-lived assets Long-Lived Assets Goodwill, impairment loss Goodwill, Impairment Loss Valuation allowances Deferred Tax Assets, Valuation Allowance Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Net unrealized gains/losses on cash flow hedges Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] 0.97% Japanese yen denominated notes due 2049 .97% Yen-denominated Notes Due 2049 [Member] .97% Yen-denominated Notes Due 2049 Acquired IPR&D Expense Payments for Asset Acquisitions Payments for Asset Acquisitions Deferred tax liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Equity investments without readily determinable fair values Equity Securities without Readily Determinable Fair Value, Amount Revenue, performance obligation, payment terms, days from date of shipment, maximum Revenue from Contract, Payment Term, Maximum Revenue from Contract, Payment Term, Maximum Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Shares issued (in shares) Preferred Stock, Shares Issued 3.875% notes due 2039 3.875% Notes Due 2039 [Member] Senior Notes Due 2039 [Member] Domestic and Puerto Rican companies contribution Domestic and Puerto Rican Contribution to Income before Income Taxes Percent contribution of most significant (domestic, including Puerto Rico) areas that contributed to the consolidated income (loss) before income taxes. Entity Emerging Growth Company Entity Emerging Growth Company U.S. Defined Benefit Plan, Equity Securities, US [Member] Defined Benefit Plan, Expected Future Benefit Payment [Abstract] Defined Benefit Plan, Expected Future Benefit Payment [Abstract] Other intangibles, net (Note 8) Carrying Amount, Net Intangible Assets, Net (Excluding Goodwill) Finished products Inventory, Finished Goods, Gross 0.625% Notes due 2031 .625% Notes due 2031 [Member] .625% Notes due 2031 [Member] Total gross deferred tax assets Deferred Tax Assets, Gross Fair value of CVR liability Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability Revenue, performance obligation, payment terms, days from date of shipment, minimum Revenue from Contract, Payment Term, Minimum Revenue from Contract, Payment Term 2024 Lessee, Operating Lease, Liability, to be Paid, Year One Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Actuarial losses Accumulated Defined Benefit Plans Adjustment, Net Gain (Loss) Including Portion Attributable to Noncontrolling Interest [Member] Title Trading Arrangement, Individual Title Common Stock Common Stock [Member] Noncurrent investments Debt Securities, Available-for-Sale, Noncurrent Individual: Individual [Axis] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Diabetes and Obesity Diabetes And Obesity [Member] Total diabetes and obesity Lapses of statutes of limitation Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations Collaboration and other revenue associated with prior period transfers of intellectual property Royalty [Member] Other noncurrent assets Derivative Asset, Noncurrent Revenue, performance obligation, sales returns, product expiration date Revenue, Performance Obligation, Sales Returns, Product Expiration Date Revenue, Performance Obligation, Sales Returns, Product Expiration Date Total equity Beginning balance Ending balance Equity, Including Portion Attributable to Noncontrolling Interest Schedule of Collaborative Arrangements Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block] Minimum Minimum [Member] Property and equipment, net (Note 9) Property and equipment, net Property, Plant and Equipment, Net Shares used in calculation of earnings per share: Weighted Average Number of Shares Outstanding, Diluted [Abstract] 1.125% Notes due 2051 1.125% euro denominated notes due 2051 1.125% Euro Denominated Notes Due 2051 [Member] 1.125% Euro Denominated Notes Due 2051 Contingent value right, additional price per share, aggregate amount Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High Disposal Group Classification [Axis] Disposal Group Classification [Axis] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Benefit obligation at beginning of year Benefit obligation at end of year Defined Benefit Plan, Benefit Obligation DICE Therapeutics, Inc. (DICE) DICE Therapeutics, Inc [Member] DICE Therapeutics, Inc Assets Assets [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] More Than 10 Years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10 Proceeds from issuance of long-term debt Proceeds from Issuance of Long-Term Debt 2025 Defined Benefit Plan, Expected Future Benefit Payment, Year Three Deferred tax assets: Deferred Tax Assets, Net [Abstract] Other Deferred Tax Assets, Other Accumulated benefit obligation Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Accumulated Benefit Obligation Net Cash Provided by (Used for) Financing Activities Net Cash Provided by (Used in) Financing Activities Deferred tax assets (Note 14) Deferred Income Tax Assets, Net Retirement Plan Type [Axis] Retirement Plan Type [Axis] Contingencies Commitments and Contingencies Disclosure [Text Block] Other investing activities, net Payments for (Proceeds from) Other Investing Activities Retained Earnings Retained Earnings [Member] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] 3.7% notes due 2045 3.7% Notes Due 2045 [Member] 3.7% Notes Due 2045 Nonoperating Income (Expense) [Abstract] Nonoperating Income (Expense) [Abstract] Foreign currency exchange rate changes and other adjustments Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss) Basic (in dollars per share) Earnings Per Share, Basic Issuance of stock under employee stock plans, net Stock Issued During Period, Value, Employee Stock Purchase Plan Accounting Policies [Abstract] Accounting Policies [Abstract] Percentage of nonperforming assets Available-for-Sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Other, Percentage of Nonperforming Assets Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Fair value of plan assets at beginning of year Fair value of plan assets at end of year Fair value of plan assets Defined Benefit Plan, Plan Assets, Amount Deferred tax assets, net Deferred Tax Assets, Net COVID-19 antibodies COVID-19 Antibodies COVID-19 Antibodies [Member] COVID-19 Antibodies BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc [Member] BioMarin Pharmaceutical Inc Total Tax Cut And Jobs Act, Toll Tax, To Be Paid Tax Cut And Jobs Act, Toll Tax, To Be Paid Fair value of securities in an unrealized gain position Debt Securities, Available-for-sale, Unrealized Gain Position Debt Securities, Available-for-sale, Unrealized Gain Position Schedule of Additional Stock-Based Compensation Disclosures Schedule of Additional Stock-Based Compensation Disclosures [Table Text Block] Schedule of Additional Stock-Based Compensation Disclosures [Table Text Block] Buy GBP Sell USD Buy GBP Sell USD [Member] Buy GBP Sell USD Audit Information [Abstract] Audit Information [Abstract] Benefits paid Defined Benefit Plan, Benefit Obligation, Benefits Paid Cash payments of income taxes Income Taxes Paid Total noncurrent liabilities Liabilities, Noncurrent Proceeds from issuance of debt Proceeds from Issuance of Debt Document Transition Report Document Transition Report Award Timing Predetermined Award Timing Predetermined [Flag] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] U.S. and Puerto Rico UNITED STATES And PUERTO RICO [Member] UNITED STATES And PUERTO RICO [Member] Summary of Income Tax Contingencies Summary of Income Tax Contingencies [Table Text Block] Emgality Patent Litigation Emgality Patent Litigation [Member] Emgality Patent Litigation [Member] Entity Public Float Entity Public Float Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Akouos Acquisition Akouos Acquisition [Member] Akouos Acquisition [Member] Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Sell Euro Sell Euro [Member] Sell Euro [Member] Derivative Instrument [Axis] Derivative Instrument [Axis] Long-term notes, gross Long-Term Debt, Gross Change in net unrealized gains (losses) on cash flow hedges Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, before Tax 1.625% Notes due 2026 1.625% Notes Due June 2, 2026 [Member] 1.625% Notes Due June 2, 2026 [Member] All Trading Arrangements All Trading Arrangements [Member] All Adjustments to Compensation All Adjustments to Compensation [Member] Orforglipron Orforglipron [Member] Orforglipron Compensation Amount Outstanding Recovery Compensation Amount Sales returns, rebates, and discounts Sales Returns and Allowances [Member] Operating lease assets Deferred Tax Liabilities, Leasing Arrangements Total deferred tax benefit Deferred Income Tax Expense (Benefit) Subsequent Event Type [Axis] Subsequent Event Type [Axis] Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Schedule of Effects of Risk-Management Instruments Were Recognized in Other–Net, (Income) Expense Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block] Document Financial Statement Error Correction Flag Document Financial Statement Error Correction [Flag] Total accumulated benefit obligation for our defined benefit pension plans Defined Benefit Plan, Accumulated Benefit Obligation Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table] Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table] 2024 Long-Term Debt, Maturity, Year One Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration] Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration] Number of sites jointly and severally liable for cleanup (fewer than) Loss Contingency, Number Of Sites Jointly And Severally Liable For Cleanup Loss Contingency, Number Of Sites Jointly And Severally Liable For Cleanup Revenue, performance obligation, sales returns, average inventory level (or less) Revenue, Performance Obligation, Sales Returns, Average Inventory Level Revenue, Performance Obligation, Sales Returns, Average Inventory Level 0.500% Notes due 2033 0.50% euro denominated notes due 2033 .5000% Euro Denominated Notes Due 2033 [Member] .5000% Euro Denominated Notes Due 2033 Equipment Machinery and Equipment, Gross Emgality® Emgality [Member] Emgality [Member] Milestone Payments, Development and Regulatory Milestone Payments, Development and Regulatory [Member] Milestone Payments, Development and Regulatory [Member] Documents Incorporated by Reference Documents Incorporated by Reference [Text Block] 1.700% Notes due 2049 1.700% Notes due 2049 [Member] 1.700% Notes due 2049 [Member] Maturity Date 2024 Maturity Date 2024 [Member] Maturity Date 2024 Document Period End Date Document Period End Date Adoption Date Trading Arrangement Adoption Date Sales rebates and discounts Sales rebates and discounts Sales rebates and discounts Common Stock in Treasury Treasury Stock, Common [Member] Reclassification out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income [Member] Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Income taxes (Note 14) Income taxes Tax benefit Income Tax Expense (Benefit) Total Derivative Instruments, Gain (Loss) Recognized Derivative Instruments, Gain (Loss) Recognized Outside U.S. Non-US [Member] Designated as Hedging Instrument Designated as Hedging Instrument [Member] Cialis® Cialis [Member] Cialis [Member] Financial Instruments Fair Value Disclosures [Text Block] Other securities, noncurrent investments Other Equity Securities [Member] Other Equity Securities [Member] Equity [Abstract] Equity [Abstract] Inventories Inventory Disclosure [Text Block] Weighted-average remaining lease term Operating Lease, Weighted Average Remaining Lease Term Acquisition date fair value of consideration transferred Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Other receivables Other Receivables, Net, Current Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Recognized actuarial (gain) loss Defined Benefit Plan, Amortization of Gain (Loss) Defined benefit obligation, period decrease Defined Benefit Plan, Benefit Obligation, Period Increase (Decrease) Change in deferred income taxes Increase (Decrease) in Deferred Income Taxes Tax credit carryforward Tax Credit Carryforward, Amount Cash and cash equivalents (Note 7) Cash and Cash Equivalents, at Carrying Value Cash paid, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Average remaining maturity of foreign currency derivatives Average Remaining Maturity of Foreign Currency Derivatives Expected return on plan assets Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-Term Rate of Return on Plan Assets Senior Notes Due 2026, 2033, 2053 And 2063 Senior Notes Due 2026, 2033, 2053 And 2063 [Member] Senior Notes Due 2026, 2033, 2053 And 2063 Purchase of treasury shares (in shares) Treasury Stock, Shares, Acquired 5.1% Notes Due 2064 5.1% Notes Due 2064 [Member] 5.1% Notes Due 2064 Estimated useful life Property, Plant and Equipment, Useful Life Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Discount rate Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate 3.375% notes due 2029 3.375% Notes Due 2029 [Member] 3.375% Notes Due 2029 Interest Rate Contract Interest Rate Contract [Member] Acquired IPR&D Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Advertising expense, percentage of revenue Advertising Expense, Percentage Of Revenue Advertising Expense, Percentage Of Revenue Schedule of Amounts Recorded for Contract Liabilities Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Intangible Assets, Net (Excluding Goodwill) [Abstract] Intangible Assets, Net (Excluding Goodwill) [Abstract] Revenue Revenue from Contract with Customer [Text Block] Settlements Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities Additional paid-in capital Additional Paid in Capital, Common Stock Additional Paid-in Capital Additional Paid-in Capital [Member] Document Annual Report Document Annual Report Cash and cash equivalents at beginning of year Cash and Cash Equivalents at End of Year Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Loss Contingencies [Line Items] Loss Contingencies [Line Items] Revision of Prior Period [Axis] Revision of Prior Period [Axis] Cover [Abstract] Cover [Abstract] Forteo® Forteo [Member] Forteo [Member] U.S. UNITED STATES Amortization of retirement benefit items Accumulated Defined Benefit Plans Adjustment Including Portion Attributable to Noncontrolling Interest [Member] Tax Credit Carryforward, Name [Domain] Tax Credit Carryforward, Name [Domain] Dividends paid Payments of Dividends Other noncurrent liabilities Other Liabilities, Noncurrent Total lease payments Lessee, Operating Lease, Liability, to be Paid Roche Roche [Member] Roche [Member] Short-term investments (Note 7) Short-Term Investments Cash flow hedges Cash Flow Hedging [Member] Shares expected to be issued (in shares) Share Based Compensation Arrangement by Share-based Payment Award, Expected Shares To Be Issued The number of shares expected to be issued in the next twelve months under the plan. Net increase (decrease) in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Buy Euro Sell USD Buy Euro Sell Us Dollar [Member] Foreign Currency Forward Commitment to Buy euro Sell US dollar Maturity Date 2027 Maturity Date, 2027 [Member] Maturity Date, 2027 Equity Component [Domain] Equity Component [Domain] State and Local Jurisdiction State and Local Jurisdiction [Member] Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Entity Current Reporting Status Entity Current Reporting Status Offsetting Assets [Line Items] Offsetting Assets [Line Items] Concentration Risk Type [Domain] Concentration Risk Type [Domain] 4.7% notes due 2033 4.7% Notes Due 2033 [Member] 4.7% Notes Due 2033 Rate of compensation increase Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase Total deferred tax liabilities Deferred Tax Liabilities, Gross Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Mounjaro® Mounjaro [Member] Mounjaro Estimate of Fair Value Measurement Estimate of Fair Value Measurement [Member] Property, Plant and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Mortgage-backed securities Collateralized Mortgage-Backed Securities [Member] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Zyprexa® Zyprexa [Member] Zyprexa [Member] Eli Lilly and Company Shareholders' Equity (Notes 12 and 13) Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] International Defined Benefit Plan, Equity Securities, Non-US [Member] Pay vs Performance Disclosure [Line Items] Entity Voluntary Filers Entity Voluntary Filers Statistical Measurement [Domain] Statistical Measurement [Domain] Derivative liability, notional amount Derivative Liability, Notional Amount Olanzapine Portfolio Olanzapine Portfolio [Member] Olanzapine Portfolio Underlying Security Market Price Change Underlying Security Market Price Change, Percent Cash Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Remaining lease term (up to) Lessee, Operating Lease, Remaining Lease Term Beam Therapeutics Inc. Beam Therapeutics, Inc. [Member] Beam Therapeutics, Inc. Borrowings Debt Disclosure [Text Block] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] 0.45% Swiss franc denominated notes due 2028 0.45% Swiss Franc Denominated Notes Due 2028 [Member] 0.45% Swiss Franc Denominated Notes Due 2028 Offsetting Assets [Table] Offsetting Assets [Table] Research and Development Expense Research and Development Expense, Policy [Policy Text Block] Cross-currency interest rate swaps Cross Currency Interest Rate Contract [Member] Hedge funds Hedge Funds [Member] Effect of exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Impairment of intangible assets, finite-lived Impairment of Intangible Assets, Finite-Lived MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Performance Shares Performance Shares [Member] 5.55% notes due 2037 5.55% Notes Due 2037 [Member] 5.55% Notes Due 2037 Accounts payable Accounts Payable, Current Real estate Defined Benefit Plan, Real Estate [Member] Restatement Determination Date: Restatement Determination Date [Axis] Corporate debt securities Corporate Debt Securities [Member] Other—net, (income) expense (Note 18) Other–net, (income) expense Nonoperating Income (Expense) Number of pending lawsuits Loss Contingency, Pending Claims, Number Commitments and Contingencies (Note 16) Commitments and Contingencies Impairment of intangible assets, indefinite-lived Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill) Construction in progress Construction in Progress, Gross Cash flow hedges: Cash Flow Hedge [Abstract] Cash Flow Hedge [Abstract] Geographical [Axis] Geographical [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Income Taxes Income Tax Disclosure [Text Block] 2027 Defined Benefit Plan, Expected Future Benefit Payment, Year Five 4.95% notes due 2063 4.95% Notes Due 2063 [Member] 4.95% Notes Due 2063 4.5% Notes Due 2029 4.5% Notes Due 2029 [Member] 4.5% Notes Due 2029 Valuation allowance release Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount Business Acquisition [Line Items] Business Acquisition [Line Items] Employee benefit trust Employee benefit trust Common Stock, Shares Held in Employee Trust Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] PEO Total Compensation Amount PEO Total Compensation Amount Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Hedging Relationship [Axis] Hedging Relationship [Axis] Land Land 6.77% notes due 2036 6.77% Notes Due 2036 [Member] 6.77% Notes Due 2036 1.70% euro denominated notes due 2049 1.7% Euro-denominated Notes Due 2049 [Member] 1.7% Euro-deonominated Notes Due 2049 [Member] Business acquisition, share price (in dollars per share) Business Acquisition, Share Price Schedule of Allocation of Plan Assets Schedule of Allocation of Plan Assets [Table Text Block] Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Beginning balance (in shares) Ending balance (in shares) Treasury Stock, Common, Shares 2023 Defined Benefit Plan, Expected Future Benefit Payment, Year One Employee Benefit Trust Trust for Benefit of Employees [Member] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Buy USD Sell Euro Buy USD Sell Euro [Member] Buy USD Sell Euro [Member] Asset impairment and other special charges Asset Impairment Charges (Recoveries) And Other Special Charges Asset Impairment Charges (Recoveries) And Other Special Charges Benefit (expense) for income taxes related to other comprehensive income (loss) Other Comprehensive Income (Loss), Tax Net income Net income Net Income (Loss) Total current liabilities Liabilities, Current Derivative, Name [Domain] Derivative Contract [Domain] Schedule of Benefit Obligations in Excess of Fair Value of Plan Assets Defined Benefit Plan, Plan with Projected Benefit Obligation in Excess of Plan Assets [Table Text Block] Foreign Currency Translation Foreign Currency Transactions and Translations Policy [Policy Text Block] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Company Selected Measure Name Company Selected Measure Name Leases Lessee, Operating Leases [Text Block] Short-term commercial paper borrowings Short-term commercial paper borrowings Commercial Paper Liabilities and Equity Liabilities and Equity [Abstract] Finite-lived intangible assets: Finite-Lived Intangible Assets [Line Items] Foreign currency exchange rate changes and other adjustments Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss) Sales rebates and discounts Deferred Tax Assets, Sales Rebates And Discounts Deferred Tax Assets, Sales Rebates And Discounts Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Axis] Net amount reclassified from accumulated other comprehensive loss Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent Unrealized gross losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] 0.625% euro denominated notes due 2031 .625% Euro-denominated Notes Due 2031 [Member] .625% Euro-deonominated Notes Due 2031 [Member] Effective portion of risk-management instruments that was recognized in other comprehensive income (loss) Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Total (approximates replacement cost) Inventory, Gross Cost of sales Cost of Goods and Services Sold Net amount recognized Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position Internal Revenue Service (IRS) Internal Revenue Service (IRS) [Member] Award vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Schedule of Indefinite-lived Intangible Assets other than Goodwill Schedule of Indefinite-Lived Intangible Assets [Table Text Block] Net losses on foreign currency exchange contracts not designated as hedging instruments Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments Foreign Exchange Contract Foreign Exchange Contract [Member] Name Measure Name 3.1% notes due 2027 3.1% Notes Due 2027 [Member] 3.1% Notes Due 2027 Name Forgone Recovery, Individual Name Purchases of short-term investments Payments to Acquire Short-Term Investments Goodwill (Note 8) Goodwill Goodwill Additions for tax positions of prior years Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions Other neuroscience Other Neuroscience [Member] Other Neuroscience [Member] Revenue recognized Disposal Group, Including Discontinued Operation, Revenue Buildings Buildings and Improvements, Gross Increase to LIFO cost Inventory, LIFO Reserve Measurement Basis [Axis] Measurement Basis [Axis] Asset Acquisition [Domain] Asset Acquisition [Domain] Underlying Securities Award Underlying Securities Amount Other Comprehensive Income (Loss) Comprehensive Income (Loss) Note [Text Block] Fair Value Measurement [Domain] Fair Value Measurement [Domain] Cash dividend declared per share (in usd per share) Common Stock, Dividends, Per Share, Declared Summary of the Contractual Maturities of Our Investments in Debt Securities Measured at Fair Value Investments Classified by Contractual Maturity Date [Table Text Block] 2.50% notes due 2060 2.5% Notes Due 2060 [Member] 2.5% Notes Due 2060 Revenue, performance obligation, sales rebate payment period (up to) Revenue, Performance Obligation, Sales Rebate Payment Period Revenue, Performance Obligation, Sales Rebate Payment Period Debt instrument, term Debt Instrument, Term Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Earnings of foreign subsidiaries Deferred Tax Liabilities, Undistributed Foreign Earnings Reclassification out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Axis] Shares held in employee trust (in shares) Common Stock, Shares Held in Employee Trust, Shares Accrued retirement benefits (Note 15) Accrued retirement benefits Liability, Defined Benefit Plan, Noncurrent Change in foreign currency translation gains (losses) Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss), before Reclassification and Tax Other assets and liabilities, net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities), Net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities), Net Revision of Prior Period, Reclassification, Adjustment Revision of Prior Period, Reclassification, Adjustment [Member] Other diabetes and obesity Other Diabetes And Obesity [Member] Other diabetes and obesity Schedule of Maturities of Operating Lease Liabilities Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Change in benefit obligation: Defined Benefit Plan, Change in Benefit Obligation [Roll Forward] Europe Europe [Member] Schedule of Fair Value, by Balance Sheet Grouping Fair Value, by Balance Sheet Grouping [Table Text Block] Product and Service [Domain] Product and Service [Domain] Other Performance Measure, Amount Other Performance Measure, Amount Number of patents Loss Contingency, Number Of Patents Loss Contingency, Number Of Patents Schedule of Impact of Leases to Consolidated Condensed Financial Statements Lease, Cost [Table Text Block] Inventories—(increase) decrease Increase (Decrease) in Inventories Cash Flows from Investing Activities Net Cash Provided by (Used in) Investing Activities [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Payment for debt extinguishment Payment for Debt Extinguishment or Debt Prepayment Cost Interest expense Interest Expense Debt extinguishment loss (Note 11) Debt extinguishment loss (Note 11) Gain (Loss) on Extinguishment of Debt Stockholders' Equity Note [Abstract] Stockholders' Equity Note [Abstract] Trading Arrangement: Trading Arrangement [Axis] Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Table] Mablink Biosciences SAS Mablink Biosciences SAS [Member] Mablink Biosciences SAS Share-based Compensation Awards, Fair Value Assumptions Used Share-based Compensation Awards, Fair Value Assumptions Used [Table Text Block] Share-based Compensation Awards, Fair Value Assumptions Used [Table Text Block] Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Entity File Number Entity File Number Loss Contingencies [Table] Loss Contingencies [Table] Unamortized note discounts Debt Instrument, Unamortized Discount After 2028 Lessee, Operating Lease, Liability, to be Paid, after Year Five 2026 Long-Term Debt, Maturity, Year Three Net unrealized gains/losses on available-for-sale securities AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member] Three Largest Wholesales Three Largest Wholesales [Member] Three Largest Wholesales [Member] Reductions for tax positions of prior years Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions Auditor Firm ID Auditor Firm ID Amortization expense Amortization of Intangible Assets Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Entity Shell Company Entity Shell Company Investments (Note 7) Noncurrent investments Long-Term Investments Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Restatement Determination Date Restatement Determination Date Additions based on tax positions related to the current year Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Expiration By 2026 Expiration By 2026 [Member] Expiration By 2026 [Member] May 2021 Share Repurchase Program May 2021 Share Repurchase Program [Member] May 2021 Share Repurchase Program Schedule of Accumulated Benefit Obligations in Excess of Fair Value of Plan Assets Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Table Text Block] Lease expense Operating Lease, Cost Common stock, shares, issued (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Issued Unrecognized net actuarial (gain) loss Defined Benefit Plan, Accumulated Other Comprehensive Income (Loss), Gain (Loss), before Tax Severance Severance Costs Summary of the Fair Value of Available-for-Sale Securities in an Unrealized Gain or Loss Position Unrealized Gain (Loss) on Investments [Table Text Block] Cost of common stock in treasury Treasury Stock, Common, Value Long-term debt Long-term debt, including current portion Total long-term notes Long-Term Debt 2027 Long-Term Debt, Maturity, Year Four Equity method investments Equity Method And Other Investments [Member] Equity Method and Other Investments [Member] Senior Notes Due 2027, 2029, 2054 And 2064 Senior Notes Due 2027, 2029, 2054 And 2064 [Member] Senior Notes Due 2027, 2029, 2054 And 2064 Foreign currency translation gains/losses Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Schedule of finite-lived Intangible Assets Amortization Expense Finite-Lived Intangible Assets Amortization Expense [Table Text Block] Change in net unrealized gains (losses) on available-for-sale securities OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax Common Stock (no par value) Common Class A [Member] Period for recognition of the compensation cost not yet recognized Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Other financing activities, net Proceeds from (Payments for) Other Financing Activities Description of derivative activity volume percent Long-Term Debt, Percentage Bearing Fixed Interest, Converted To Floating Rate Long-Term Debt, Percentage Bearing Fixed Interest, Converted To Floating Rate Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Schedule of Expected Benefit Payments Schedule of Expected Benefit Payments [Table Text Block] Funded status Defined Benefit Plan, Funded (Unfunded) Status of Plan Variable rate Long-Term Debt, Percentage Bearing Variable Interest, Percentage Rate Acquired IPR&D Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Acquired In Process Research And Development Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Acquired In Process Research And Development Schedule of Change in Accounting Estimate [Table] Schedule of Change in Accounting Estimate [Table] Entity Address, Address Line One Entity Address, Address Line One Acquisitions Asset Acquisition [Text Block] Fair value of plan assets Fair value of plan assets Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets Prior service benefits, net Accumulated Defined Benefit Plans Adjustment, Net Prior Service Including Portion Attributable to Noncontrolling Interest [Member] Cost Portion at Other than Fair Value Measurement [Member] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Statement [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Accumulated other comprehensive (income) loss before income taxes Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, before Tax Subsequent Event Subsequent Event [Member] Accruals for the payment of interest and penalties Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued Operating loss carryforwards Operating Loss Carryforwards Schedule of Finite-lived Intangible Assets other than Goodwill Schedule of Finite-Lived Intangible Assets [Table Text Block] Other current liabilities Other Liabilities, Current Income Statement [Abstract] Income Statement [Abstract] Defined Benefit Plan, Plan Assets, Category [Axis] Defined Benefit Plan, Plan Assets, Category [Axis] Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Components of net periodic (benefit) cost: Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract] Stock-based compensation Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Dividends payable Dividends Payable, Current Other current assets Other Assets, Current Schedule of Cash Payments Relating to Income Taxes and Tax Act Toll Tax Schedule of Additional Income Tax Disclosures [Table Text Block] Schedule of Additional Income Tax Disclosures [Table Text Block] 2.75% notes due 2025 2.75% Notes Due 2025 [Member] 2.75% Notes Due 2025 Income tax at the U.S. federal statutory tax rate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount Other noncurrent assets Assets for Plan Benefits, Defined Benefit Plan Add (deduct): Add (Deduct) [Abstract] Add (Deduct) [Abstract] Current: Current Federal, State and Local, Tax Expense (Benefit) [Abstract] Total debt Debt, Long-Term and Short-Term, Combined Amount Inventories (Note 6) Inventories Inventory, Net Swap Swiss Francs to USD Swap Swiss Francs To U.S. Dollars [Member] Swap Swiss Francs To U.S. Dollars [Member] Financial Instrument [Axis] Financial Instrument [Axis] Advertising Expenses Advertising Cost [Policy Text Block] Erbitux® Erbitux [Member] Erbitux [Member] Total Shareholder Return Amount Total Shareholder Return Amount Purchases of common stock Payments for Repurchase of Common Stock Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Retirement of treasury shares Treasury Stock, Retired, Cost Method, Amount Foreign Deferred Foreign Income Tax Expense (Benefit) Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Developed markets Fixed Income Funds [Member] Maximum remaining maturity of foreign currency derivatives Maximum Remaining Maturity of Foreign Currency Derivatives Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Schedule of Other Nonoperating Income (Expense) Schedule of Other Nonoperating Income (Expense) [Table Text Block] Retained earnings Retained Earnings (Accumulated Deficit) Proceeds from sales and maturities of short-term investments Proceeds from Sale of Short-Term Investments Debt instrument, face amount Debt Instrument, Face Amount Current Assets Assets, Current [Abstract] Leases [Abstract] Leases [Abstract] Costs, expenses, and other Cost of sales, operating expenses, and other-net Cost of sales, operating expenses, and other-net Entity Address, State or Province Entity Address, State or Province Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Cash Flows from Operating Activities Net Cash Provided by (Used in) Operating Activities [Abstract] Royalty Payments Received Royalty Agreement Terms [Member] Disposal Group Name [Domain] Disposal Group Name [Domain] Receivables—(increase) decrease Increase (Decrease) in Accounts and Other Receivables Long-term notes Notes Payable 1.625% Notes due 2043 1.625% British Pound Denominated Notes Due 2043 [Member] 1.625% British Pound Denominated Notes Due 2043 Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Class of Stock [Domain] Class of Stock [Domain] Customer [Domain] Customer [Domain] Schedule of Amounts Recognized in Other Comprehensive Loss Reclassification out of Accumulated Other Comprehensive Income [Table Text Block] Schedule of Inventory Schedule of Inventory, Current [Table Text Block] Revenues from External Customers and Long-Lived Assets [Line Items] Revenues from External Customers and Long-Lived Assets [Line Items] Total Operating Lease, Liability Change in retirement benefit plans (Note 15) Total other comprehensive income (loss) during period Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax Asset Acquisition [Axis] Asset Acquisition [Axis] Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standards Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Cash value of trust owned insurance contract Other Contract [Member] Consideration received Disposal Group, Including Discontinued Operation, Consideration Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Expense under the plans Defined Contribution Plan, Cost Purchases of property and equipment Payments to Acquire Other Property, Plant, and Equipment All Executive Categories All Executive Categories [Member] Other Other Product, Total [Member] Other Product, Total [Member] Other Effective Income Tax Rate Reconciliation, Other Adjustments, Amount Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] 4.65% notes due 2044 4.65% Notes Due 2044 [Member] 4.65% Notes Due 2044 Retirement benefit plans Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Tax benefit Share-Based Payment Arrangement, Expense, Tax Benefit 2.25% notes due 2050 2.25% Notes Due 2050 [Member] 2.25% Notes Due 2050 [Member] Earnings per share: Earnings Per Share [Abstract] Effect from hedged fixed-rate debt Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge Common stock—no par value Authorized shares: 3,200,000 Issued shares: 949,781 (2023) and 950,632 (2022) Common Stock, Value, Issued 1-5 Years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five Investments Valued at Net Asset Value Fair Value Measured at Net Asset Value Per Share [Member] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Deferred tax assets related to state net operating losses Deferred Tax Assets, Operating Loss Carryforwards, State and Local Senior Notes Senior Notes [Member] Schedule of Defined Benefit Plans Disclosures [Table] Schedule of Defined Benefit Plans Disclosures [Table] Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] All Individuals All Individuals [Member] Humalog, Humulin and Forteo Humalog, Humulin, And Forteo [Member] Humalog, Humulin, And Forteo Percentage of global investments in plan assets Defined Benefit Plan, Percentage of Global Investments in Plan Assets Percentage description of US defined benefit and other postretirement plan assets as compared to the total global investment balance Other, net (income) expense Other (income) expense Other Nonoperating Income (Expense) Litigation Case Type [Domain] Litigation Case [Domain] Equity-like funds Equity Funds [Member] Entity Filer Category Entity Filer Category Cyramza® Cyramza [Member] Cyramza [Member] 2.125% Notes due 2030 2.125% Notes Due June 3, 2030 [Member] 2.125% Notes Due June 3, 2030 [Member] Milestone Payments, Sales-based Milestone Payments, Sales-based [Member] Milestone Payments, Sales-based [Member] Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Statement [Table] Statement [Table] Current Fiscal Year End Date Current Fiscal Year End Date Stock repurchase program, authorized amount Stock Repurchase Program, Authorized Amount Schedule of Effective Income Tax Rate Reconciliation Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Effect from interest rate contracts Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments Schedule of Effective Portion of Risk-Management Instruments that was Recognized in Other Comprehensive Income (Loss), Cash Flow Hedges Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block] Beginning balance Ending balance Unrecognized Tax Benefits Income Tax Authority [Axis] Income Tax Authority [Axis] PEO Name PEO Name Other Other Product [Member] Other Product [Member] Operating lease liabilities Deferred Tax Assets, Operating Lease, Liability Deferred Tax Assets, Operating Lease, Liability Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Baqsimi Baqsimi [Member] Baqsimi Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized 2029-2033 Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years Building Building [Member] Tax credit carryforwards Deferred Tax Assets, Tax Credit Carryforwards Short-term investments Debt Securities, Available-for-Sale, Current Actuarial gain (loss) arising during period Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax Purchases of noncurrent investments Payments to Acquire Other Investments Long-term income taxes payable, estimated timing of future cash outflows not possible Accrued Income Taxes, Noncurrent, Estimated Timing Of Future Cash Outflows Not Possible Accrued Income Taxes, Noncurrent, Estimated Timing Of Future Cash Outflows Not Possible Stated interest rate Debt Instrument, Interest Rate, Stated Percentage Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Contingent value right, additional price per share (in dollars per share) Business Acquisition, Contingent Value Right, Additional Price Per Share Business Acquisition, Contingent Value Right, Additional Price Per Share 3.95% notes due 2047 3.95% Notes Due 2047 [Member] 3.95% Notes Due 2047 Total Eli Lilly and Company shareholders' equity Beginning balance Ending balance Equity, Attributable to Parent Unrecognized tax benefits that would impact effective tax rate Unrecognized Tax Benefits that Would Impact Effective Tax Rate Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Revision of Prior Period [Domain] Revision of Prior Period [Domain] Income before income taxes Total before tax Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Other-Net, (Income) Expense Other Income and Other Expense Disclosure [Text Block] Maturities on long-term debt Long-Term Debt, Fiscal Year Maturity [Abstract] Not Designated as Hedging Instrument Not Designated as Hedging Instrument [Member] Schedule of Amounts Recognized in Other Comprehensive Income (Loss) Schedule of Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block] Other current liabilities Liability, Defined Benefit Plan, Current Hedging Designation [Domain] Hedging Designation [Domain] Emerging markets Fixed Income Funds Emerging Markets [Member] An investment that pools funds from many investors to invest in a combination of underlying investments, primarily fixed income investments in EMERGING MARKETS. Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Net investment hedges Net Investment Hedging [Member] Long-lived Assets by Geographic Areas Long-Lived Assets by Geographic Areas [Table Text Block] Amortization of prior service (benefit) cost included in net income Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax Retirement of treasury shares (in shares) Treasury Stock, Shares, Retired Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration] Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration] Disposal Group Classification [Domain] Disposal Group Classification [Domain] Debt instrument, interest rate, effective percentage Debt Instrument, Interest Rate, Effective Percentage Changes related to the impact of foreign currency translation Unrecognized Tax Benefits, Increase Resulting from Foreign Currency Translation Increase (Decrease) in Shareholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Asset Impairment, Restructuring, And Other Special Charges Restructuring, Impairment, and Other Activities Disclosure [Text Block] Document Fiscal Period Focus Document Fiscal Period Focus Finite-lived intangible asset, useful life (in years) Finite-Lived Intangible Asset, Useful Life Line of credit facility, remaining borrowing capacity Line of Credit Facility, Remaining Borrowing Capacity 2027 Lessee, Operating Lease, Liability, to be Paid, Year Four Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Foreign Tax Authority Foreign Tax Authority [Member] Long-term income taxes payable (Note 14) Accrued Income Taxes, Noncurrent City Area Code City Area Code Product and Service [Axis] Product and Service [Axis] Document Fiscal Year Focus Document Fiscal Year Focus Geographical [Domain] Geographical [Domain] Share Repurchase Program [Domain] Share Repurchase Program [Domain] Exercise Price Award Exercise Price Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Equity securities Equity Securities, FV-NI, Noncurrent Net income Total reclassifications for the period, net of tax Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Other immunology Other Immunology [Member] Other Immunology Schedule of Fair Value Information, Assets Fair Value, Assets Measured on Recurring Basis [Table Text Block] Marketed products Developed Technology Rights [Member] Total liabilities and equity Liabilities and Equity Other noncurrent assets Other Assets, Noncurrent Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Emergence Therapeutics AG Emergence Therapeutics [Member] Emergence Therapeutics Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Remaining amortization period (in years) Finite-Lived Intangible Assets, Remaining Amortization Period Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Foreign Current Foreign Tax Expense (Benefit) Indefinite-lived Intangible Assets [Line Items] Indefinite-Lived Intangible Assets [Line Items] Discount rate Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate Arrangement Duration Trading Arrangement Duration Acquired IPR&D In Process Research and Development [Member] Entity Address, City or Town Entity Address, City or Town Award Timing MNPI Considered Award Timing MNPI Considered [Flag] 5.5% notes due 2027 5.5% Notes Due 2027 [Member] 5.5% Notes Due 2027 General business credits Effective Income Tax Rate Reconciliation, Tax Credit, Amount Change in Accounting Estimate, Type [Domain] Change in Accounting Estimate, Type [Domain] Foreign Currency Denominated Debt Foreign Currency Denominated Debt [Member] Foreign Currency Denominated Debt [Member] Investment Fair Value of Financial Instruments, Policy [Policy Text Block] Remaining authorized repurchase amount Stock Repurchase Program, Remaining Authorized Repurchase Amount Termination Date Trading Arrangement Termination Date Common stock, shares authorized (in shares) Common Stock, Shares Authorized Total Debt Securities, Available-for-Sale Raw materials and supplies Inventory, Raw Materials, Gross Document Information [Table] Document Information [Table] Unrealized gross gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Schedule of Effective Portion of Risk-Management Instruments that was Recognized in Other Comprehensive Income (Loss), Net Investment Hedges Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block] Net investment gains (loss) on equity securities Net investment (gains) losses on equity securities (Note 7) Equity Securities, FV-NI, Gain (Loss) Indefinite-lived Intangible Assets [Axis] Indefinite-Lived Intangible Assets [Axis] Donald Zakrowski [Member] Donald Zakrowski Adjustments to Reconcile Net Income to Cash Flows from Operating Activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Losses expected to be reclassified in the next 12 months Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net Derivative [Line Items] Derivative [Line Items] Award Timing Disclosures [Line Items] Foreign tax redeterminations Deferred Tax Assets, Foreign Tax Redeterminations Deferred Tax Assets, Foreign Tax Redeterminations Net investment (gains) losses Gain (Loss) on Investments Reclassification [Table] Reclassification [Table] 6-10 Years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10 Document Information [Line Items] Document Information [Line Items] Short-term Debt, Type [Axis] Short-Term Debt, Type [Axis] Tyvyt® TYVYT [Member] TYVYT Income Taxes Income Tax, Policy [Policy Text Block] Short-term borrowings and current maturities of long-term debt (Note 11) Less current portion Debt, Current 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Three Work in process Inventory, Work in Process, Gross Current federal tax expense, utilization of net operating loss carryforward Current Federal Tax Expense (Benefit), Utilization Of Net Operating Loss Carryforward Current Federal Tax Expense (Benefit), Utilization Of Net Operating Loss Carryforward Debt Instrument, Redemption, Period [Domain] Debt Instrument, Redemption, Period [Domain] Correlative tax adjustments Deferred Tax Assets, Corrective Tax Adjustments Deferred Tax Assets, Corrective Tax Adjustments Insider Trading Arrangements [Line Items] Oncology Oncology [Member] Revenue to unaffiliated customers, Oncology Entity Registrant Name Entity Registrant Name Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Award Timing Method Award Timing Method [Text Block] Other assets—(increase) decrease Increase (Decrease) in Other Operating Assets 2025 Finite-Lived Intangible Asset, Expected Amortization, Year Two Acquired In-Process Research and Development (IPR&D) In Process Research and Development, Policy [Policy Text Block] Shareholder Value Awards Shareholder Value Awards [Member] Shareholder Value Awards are granted to officers and management and are payable in shares of common stock at the end of a 3 yr period. Adjustment to Compensation, Amount Adjustment to Compensation Amount Deferred tax liabilities: Components of Deferred Tax Liabilities [Abstract] Noncontrolling interests Equity, Attributable to Noncontrolling Interest Net change in short-term borrowings Proceeds from (Repayments of) Short-Term Debt Auditor Name Auditor Name 2017 Tax Act Toll Tax Tax Cut And Jobs Act, Toll Tax, Payment, Due [Abstract] Tax Cut And Jobs Act, Toll Tax, Payment, Due Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Less accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Disposal Group Name [Axis] Disposal Group Name [Axis] Repayments of long-term debt Repayments of Long-Term Debt 6.77% Notes due 2036 6.77% Notes Due January 1, 2036 [Member] 6.77% Notes Due January 1, 2036 [Member] Entity Central Index Key Entity Central Index Key Stock-based compensation expense Share-Based Payment Arrangement, Expense Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Carrying Amount, Gross Finite-Lived Intangible Assets, Gross Income Tax Authority [Domain] Income Tax Authority [Domain] Retirement benefit plans Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component Employee compensation Employee-related Liabilities, Current Foreign currency-denominated notes, designated as hedge Derivatives used in Net Investment Hedge, Net of Tax Revenue Benchmark Revenue Benchmark [Member] Name Trading Arrangement, Individual Name Other comprehensive income (loss), net of tax (Note 17) Other comprehensive income (loss), net of tax Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Schedule of Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Other, net of tax Accumulated Net Gain (Loss) from Cash Flow Hedges and Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member] Accumulated Net Gain (Loss) from Cash Flow Hedges and Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member] International operations, including Puerto Rico Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount Entity [Domain] Entity [Domain] Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Amendment Flag Amendment Flag Legal Entity [Axis] Legal Entity [Axis] Relative Value Awards Relative Value Awards [Member] Relative Value Awards Fair value hedges Fair Value Hedging [Member] Collaboration and other revenue Collaboration and Other Revenue [Member] Collaboration and Other Revenue [Member] Purchases of intangible assets Deferred Tax Assets, Goodwill and Intangible Assets Weighted-average discount rate Operating Lease, Weighted Average Discount Rate, Percent Cash payments for interest on borrowings Interest Paid, Excluding Capitalized Interest, Operating Activities Shares issued in period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period Less Than 1 Year Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One Consideration transferred, number of contingent value rights Business Combination, Consideration Transferred, Number Of Contingent Value Rights Business Combination, Consideration Transferred, Number Of Contingent Value Rights Business Combinations Business Combinations Policy [Policy Text Block] Long-term debt (Note 11) Long-term debt Long-Term Debt, Excluding Current Maturities Actual return on plan assets Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss) Schedule of Activity Related to Our Available-for-Sale Securities Gain (Loss) on Securities [Table Text Block] Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Amortization of net actuarial (gain) loss included in net income Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), after Reclassification Adjustment, before Tax Change in Accounting Estimate [Line Items] Change in Accounting Estimate [Line Items] Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] 2024 Tax Cut And Jobs Act, Toll Tax, To Be Paid, Within One Year Tax Cut And Jobs Act, Toll Tax, To Be Paid, Within One Year Prevail Therapeutics Inc. Prevail Therapeutics Inc. [Member] Prevail Therapeutics Inc. Humulin® Humulin [Member] Humulin [Member] Humalog® Humalog [Member] Humalog [Member] Jardiance Jardiance [Member] Jardiance [Member] Company Selected Measure Amount Company Selected Measure Amount 2026 Defined Benefit Plan, Expected Future Benefit Payment, Year Four Total assets Assets Name Awards Close in Time to MNPI Disclosures, Individual Name Share Repurchase Program [Axis] Share Repurchase Program [Axis] Equipment Equipment [Member] 2028 Long-Term Debt, Maturity, Year Five Trajenta Trajenta (BI) [Member] Trajenta (BI) [Member] Restructuring and Related Activities [Abstract] Restructuring and Related Activities [Abstract] 5.0% Notes Due 2054 5.0% Notes Due 2054 [Member] 5.0% Notes Due 2054 Non-NEOs Non-NEOs [Member] Other comprehensive income (loss) before income taxes Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent Defined Benefit Plan, Plan Assets, Category [Domain] Defined Benefit Plan, Plan Assets, Category [Domain] Defined Benefit Pension Plans Pension Plan [Member] Cash Flows from Financing Activities Net Cash Provided by (Used in) Financing Activities [Abstract] Other Define Benefit Plan, Other [Member] Define Benefit Plan, Other [Member] Non-PEO NEO Non-PEO NEO [Member] Plan assets, target allocation Defined Benefit Plan, Plan Assets, Target Allocation, Percentage Adjustment to Compensation: Adjustment to Compensation [Axis] Schedule of Changes in Accumulated Postemployment Benefit Obligations Schedule of Changes in Accumulated Postemployment Benefit Obligations [Table Text Block] Tax loss and other tax carryforwards Deferred Tax Assets, Operating Loss Carryforwards Debt Instrument [Line Items] Debt Instrument [Line Items] Debt Instrument [Line Items] Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Unamortized debt issuance costs Unamortized Debt Issuance Expense Property and equipment Deferred Tax Liabilities, Property, Plant and Equipment Reclassifications Reclassification, Comparability Adjustment [Policy Text Block] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] 4.7% Notes Due 2034 4.7% Notes Due 2034 [Member] 4.7% Notes Due 2034 Developed markets - repurchase agreements Fixed Income Funds - Repurchased Agreements [Member] Fixed Income Funds - Repurchased Agreements [Member] Schedule of Indefinite-Lived Intangible Assets [Table] Schedule of Indefinite-Lived Intangible Assets [Table] 0.56% Japanese yen denominated notes due 2034 .56% Yen-denominated Notes Due 2034 [Member] .56% Yen-denominated Notes Due 2034 [Member] Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Abstract] Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Abstract] Estimated amortization expense Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Statement [Line Items] Statement [Line Items] Deferred: Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract] Cash paid for acquisitions, net of cash acquired (Note 3) Other Payments to Acquire Businesses Foreign-derived intangible income deduction Effective Income Tax Rate Reconciliation, FDII, Amount Schedule of Derivative Instruments Schedule of Derivative Instruments [Table Text Block] Schedule of Debt Schedule of Debt [Table Text Block] Reclassification out of Accumulated Other Comprehensive Income [Domain] Reclassification out of Accumulated Other Comprehensive Income [Domain] Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment and Tax [Abstract] Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment and Tax [Abstract] Noncontrolling Interest Noncontrolling Interest [Member] Tax Credit Carryforward [Axis] Tax Credit Carryforward [Axis]